Neuroone Medical Technologies Corp Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Ben Haynor - Alliance Global Partners - Analyst : Good afternoon, gentlemen. Thanks for taking my questions. First one for me, congrats on getting the first sEEG cases done and some of the Zimmer. Can you talk a little bit about the stocking situation at Zimmer. I mean, do you expect additional shipments during the current quarter or are they pretty good for the time being? How would you characterize the situation at the moment?

Question: Ben Haynor - Alliance Global Partners - Analyst : Okay. That's helpful. And then you mentioned there's been a handful of cases now, any kind of feedback that you can share all those cases have gone?

Question: Ben Haynor - Alliance Global Partners - Analyst : Okay. That's good color. And then finally, upcoming milestones that you mentioned in the press release. The expanded sales training for the sEEG product line of the Zimmer sales force, how broad does that go? I mean, is that basically just to the folks that are selling the robots, or does it go beyond that?

Question: Ben Haynor - Alliance Global Partners - Analyst : And so the training that's going to take place is that for both groups or?

Question: Ben Haynor - Alliance Global Partners - Analyst : Okay. Got it. Lastly for me and I'll jump back in queue. But the one on the water, testing with the 15 neurosurgeons, I was looking for the feedback that you've gotten there. I mean, were the comments fairly similar between the neurosurgeons that were testing it out and then what do you have kind of left to do there? I know there's -- I think you're going to do some more testing, more surgeon presentation or something. Can you talk more about that?

Question: Ben Haynor - Alliance Global Partners - Analyst : Okay, got it. That's all I have for the moment and thank you very much for taking the questions, guys.